vs
Side-by-side financial comparison of Nixxy, Inc. (NIXX) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $51.1M, roughly 1.5× Nixxy, Inc.). On growth, Nixxy, Inc. posted the faster year-over-year revenue change (10630.2% vs 27.7%). Over the past eight quarters, Nixxy, Inc.'s revenue compounded faster (1415.7% CAGR vs 31.3%).
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
NIXX vs PBYI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $51.1M | $75.5M |
| Net Profit | $-4.0M | — |
| Gross Margin | — | 69.3% |
| Operating Margin | -4.1% | 22.7% |
| Net Margin | -7.8% | — |
| Revenue YoY | 10630.2% | 27.7% |
| Net Profit YoY | 46.8% | — |
| EPS (diluted) | $-0.11 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $51.1M | $75.5M | ||
| Q3 25 | $31.9M | $54.5M | ||
| Q2 25 | $13.5M | $52.4M | ||
| Q1 25 | $1.4M | $46.0M | ||
| Q4 24 | $-485.5K | $59.1M | ||
| Q3 24 | $135.9K | $80.5M | ||
| Q2 24 | $133.1K | $47.1M | ||
| Q1 24 | $222.6K | $43.8M |
| Q4 25 | $-4.0M | — | ||
| Q3 25 | $-2.2M | $8.8M | ||
| Q2 25 | $-4.2M | $5.9M | ||
| Q1 25 | $-4.5M | $3.0M | ||
| Q4 24 | $-7.5M | — | ||
| Q3 24 | $-13.3M | $20.3M | ||
| Q2 24 | $-1.0M | $-4.5M | ||
| Q1 24 | $-778.4K | $-4.8M |
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | 100.0% | 63.9% | ||
| Q2 24 | 100.0% | 77.4% | ||
| Q1 24 | 98.6% | 75.5% |
| Q4 25 | -4.1% | 22.7% | ||
| Q3 25 | -6.8% | 17.6% | ||
| Q2 25 | -20.3% | 12.7% | ||
| Q1 25 | -341.9% | 8.7% | ||
| Q4 24 | 1130.7% | 22.6% | ||
| Q3 24 | -4042.6% | 27.4% | ||
| Q2 24 | -738.7% | -4.6% | ||
| Q1 24 | -473.3% | -5.3% |
| Q4 25 | -7.8% | — | ||
| Q3 25 | -6.8% | 16.2% | ||
| Q2 25 | -30.9% | 11.2% | ||
| Q1 25 | -325.2% | 6.5% | ||
| Q4 24 | 1542.7% | — | ||
| Q3 24 | -9795.0% | 25.2% | ||
| Q2 24 | -762.8% | -9.6% | ||
| Q1 24 | -349.8% | -11.0% |
| Q4 25 | $-0.11 | $0.26 | ||
| Q3 25 | $-0.10 | $0.17 | ||
| Q2 25 | $-0.22 | $0.12 | ||
| Q1 25 | $-0.30 | $0.06 | ||
| Q4 24 | $-0.41 | $0.40 | ||
| Q3 24 | $-2.66 | $0.41 | ||
| Q2 24 | $-0.35 | $-0.09 | ||
| Q1 24 | $-0.40 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $343.0K | $97.5M |
| Total DebtLower is stronger | $0 | $22.7M |
| Stockholders' EquityBook value | $8.0M | $130.3M |
| Total Assets | $13.2M | $216.3M |
| Debt / EquityLower = less leverage | 0.00× | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $343.0K | $97.5M | ||
| Q3 25 | $30.9K | $94.4M | ||
| Q2 25 | $98.5K | $96.0M | ||
| Q1 25 | $144.1K | $93.2M | ||
| Q4 24 | $142.0K | $101.0M | ||
| Q3 24 | $135.6K | $96.7M | ||
| Q2 24 | $240.3K | $96.8M | ||
| Q1 24 | $273.6K | $107.2M |
| Q4 25 | $0 | $22.7M | ||
| Q3 25 | $0 | $34.0M | ||
| Q2 25 | $1.2M | $45.3M | ||
| Q1 25 | $1.2M | $56.7M | ||
| Q4 24 | $1.2M | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
| Q4 25 | $8.0M | $130.3M | ||
| Q3 25 | $10.4M | $115.3M | ||
| Q2 25 | $6.6M | $104.7M | ||
| Q1 25 | $5.4M | $97.1M | ||
| Q4 24 | $2.6M | $92.1M | ||
| Q3 24 | $6.8M | $71.1M | ||
| Q2 24 | $2.6M | $48.5M | ||
| Q1 24 | $3.0M | $51.0M |
| Q4 25 | $13.2M | $216.3M | ||
| Q3 25 | $16.1M | $202.9M | ||
| Q2 25 | $13.3M | $194.9M | ||
| Q1 25 | $11.8M | $196.2M | ||
| Q4 24 | $7.0M | $213.3M | ||
| Q3 24 | $11.2M | $220.7M | ||
| Q2 24 | $9.8M | $205.0M | ||
| Q1 24 | $10.1M | $214.1M |
| Q4 25 | 0.00× | 0.17× | ||
| Q3 25 | 0.00× | 0.30× | ||
| Q2 25 | 0.18× | 0.43× | ||
| Q1 25 | 0.22× | 0.58× | ||
| Q4 24 | 0.47× | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-516.0K | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-516.0K | $14.4M | ||
| Q3 25 | $-1.0M | $9.7M | ||
| Q2 25 | $-1.2M | $14.1M | ||
| Q1 25 | $-1.8M | $3.6M | ||
| Q4 24 | $-2.4M | $15.6M | ||
| Q3 24 | $-482.9K | $11.0M | ||
| Q2 24 | $-554.6K | $1.0M | ||
| Q1 24 | $-669.8K | $11.2M |
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | — |
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
